Our Commitment to Safety and Transparency as We Study Our Investigational COVID-19 Vaccine Candidate
Learn More
Share
Johnson & Johnson by the Numbers
Learn more about how we care for the world—one person at a time—through these company fast facts.
Alex Gorsky assumed his current position as Chairman and CEO of Johnson & Johnson in 2012. He is the ninth leader of Johnson & Johnson since it was founded in 1886. Learn more about Alex and our leadership team.
In 2017, Johnson & Johnson opened the doors to Our Story at the Power House, a state-of-the-art physical exhibition at our world headquarters. The company also launched an interactive museum—ourstory.jnj.com— that celebrates over 130 years of innovations that have changed the course of human health.
We operate Johnson & Johnson Innovation, JLABS health sciences incubators in nine North American and European locales; JLABS @ Shanghai will open in 2019.
Johnson & Johnson’s consumer brands are often the first and most personal experience people have with our company. Our baby care, beauty, oral care, self-care, women’s health and wound care brands have been trusted by consumers and healthcare professionals for more than 100 years.
At the Janssen Pharmaceutical Companies of Johnson & Johnson, we’re creating a future where disease is a thing of the past. We work tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.
As the world’s most comprehensive medical devices business, we leverage our expertise across eye health, interventional solutions, orthopaedics and surgery.
More From Johnson & Johnson
June 03, 2020
Think you are up to speed on the novel coronavirus? Take this quiz to test your virus knowledge.
July 30, 2020
A preclinical study just published in Nature shows that the company's investigational vaccine has shown positive early data for eliciting an immune response against SARS-CoV-2, the virus that causes COVID-19. We share more about the findings from the recent preclinical study, along with other up-to-date information about the potential vaccine candidate.
September 08, 2020
In signing the pledge, we are joining eight other biopharmaceutical companies working on vaccine research and development in making the safety and well-being of vaccinated individuals our top priority.
